Bicyclic pyridine and pyrimidine P38 kinase inhibitors

Details Bicyclic pyridine and pyrimidine P38 kinase inhibitors Bicyclic pyridine and pyrimidine P38 kinase inhibitors

2005-11-30

2008-10-21

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S265100, C514S300000, C514S301000, C514S302000, C546S114000, C546S115000, C546S116000, C546S118000, C544S278000, C544S280000

Reexamination Certificate

active

07439247

ABSTRACT:
The present invention discloses compounds corresponding to formulawherein A, R, X, Y, R, R1and R2are as defined above, pharmaceutical formulations, methods of making and uses thereof.

REFERENCES:
patent: 2001/0020030 (2001-09-01), Stewart et al.
patent: 2005/0004142 (2005-01-01), Adams et al.
patent: WO 95/29897 (1995-11-01), None
patent: WO 95/33748 (1995-12-01), None
patent: WO 95/33752 (1995-12-01), None
patent: WO 98/01428 (1998-01-01), None
patent: WO 98/08382 (1998-03-01), None
patent: WO 00/39108 (2000-07-01), None
patent: WO 00/43394 (2000-07-01), None
patent: WO 01/49688 (2001-07-01), None
patent: WO 02/14317 (2002-02-01), None
Esper A.M; Expert. Opin. Investig. Drugs, 2005, 14(5), 633-645).
Palmer, Trends in Pharmacological Sciences, 2002, 23(9), 426-433.
Jones et al, “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
Henry, James R., et al., “6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor”,J. Med. Chem, 1998, 41: 4196-4198.
Koch, A., et al., “Effect of smoking on Map kinase-induced modulation of IL-8 in human alveolar macrophages”,Eur. Respir. J., 2004, 23: 805-812.
Noble, Martin E. M., et al., “Protein Kinase Inhibitors: Insights into Drug Design from Structure”, Science, 2004, 303: 1800-1804.
Trejo, Alejandra, et al., “Design and Synthesis of 4-Azaindoles as Inhibitors of p38 Map Kinase”,J. Med. Chem., 2003, 46: 4702-4713.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
J. W. Fijen, J. G. Zijlstra, P. De Boer, R. Spanjersberg, J. W. Cohen Tervaert, T. S. Van Der Werf, J. J. M. Ligtenberg & J. E. Tulleken, Clinical & Experimental Immunology vol. 124 Issue 1 p. 16—Apr. 2001.
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S., Gastroenterology. Jan. 2002;122(1):7-14..PMID: abstract 11781274.
Hashimoto S. Gon Y, Matsumoto K, Maruoka S, Takeshita I, Hayashi S, Asai Y, Jibiki I, Machino T, Horie T., J Pharmacol Exp Ther. May 2000;293(2):370-5.
Hurst, Derek T. An Introduction to the Chemistry and Biochemistry of the Pyrimidines, Purines, and Pteridines, London: John Wiley and Sons. 1980 pp. 26-27.
Ganghyeok Kim et al, “Design, Synthesis, and Evaluation of 1,5-Disu”,Array Biopharma, [online] no date [retrieved on Apr. 28, 2005]. Retrieved from the Internet, <http://media.corporate-ir.net/media—files
sd/arry/posters/0304ACS-Anaheim-Poster.pdf>.
Michael Greer, “HIV/AIDS Dementia: CPI-1189 safe but ineffective”, AidsWeekly Plus; [online] AidsWeekly Plus; Monday, Jan. 20, 2003 [retrieved on Apr. 28, 2005]. Retrieved from the Internet, <http://www.aegis.com/pubs/aidswkly/2003/AW030107.html>.

Affiliated with

Also associated with

Rating

Bicyclic pyridine and pyrimidine P38 kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic pyridine and pyrimidine P38 kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyridine and pyrimidine P38 kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4017939